Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain PAH Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedColorado Rocky Mountain Health PlansPolicy N/A

    Prior Authorization/Medical Necessity – PAH Agents

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity requirements for selected oral, inhaled, and injectable pulmonary hypertension agents used for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), including members continuing established therapy.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyPrior Authorization/Medical Necessity – PAH Agents
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewAug 1, 2025
    Next Review DateN/A
    Key ActionSubmit documentation of the applicable diagnosis, required diagnostic confirmation, current therapy or clinical benefit, and specialist prescribing or consultation when seeking authorization.
    SourceLink
    POLICY UPDATE CHANGES

    Yutrepia was added to the coverage criteria as a covered product.

    Yutrepia was removed from the list of products typically excluded from coverage.

    Brand Opsumit was added to the list of products typically excluded from coverage.

    5PAH medication classes described
    WHO Group 1Primary PAH population addressed
    12 monthsAuthorization period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Right heart catheterizationRequired diagnostic confirmation
    3 specialistsRequired specialist involvement

    Coverage Criteria

    PAH Initial Authorization

    Covered for initial pulmonary arterial hypertension (PAH) authorization when ALL applicable criteria in ONE of the product-specific pathways below are met.

    ONE of the following pathways

    • For Adempas, Letairis, Opsumit, Opsynvi, Tracleer, Tyvaso, Tyvaso DPI, Ventavis, or Yutrepia

      • Pulmonary arterial hypertension is symptomatic.
      • Diagnosis of pulmonary arterial hypertension is confirmed by right heart catheterization.
      • The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    • Current-therapy pathway for Adempas, Letairis, Opsumit, Opsynvi, Tracleer, Tyvaso, Tyvaso DPI, Ventavis, or Yutrepia

      • Patient is currently receiving any therapy for the diagnosis of pulmonary arterial hypertension.
      • The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    • For Revatio oral powder for suspension, Liqrev oral suspension, or Tadliq oral suspension

      • ONE of the following

        • ALL of the following

          • Pulmonary arterial hypertension is symptomatic.
          • Diagnosis of pulmonary arterial hypertension is confirmed by right heart catheterization.
        • Patient is currently receiving any therapy for the diagnosis of pulmonary arterial hypertension.
      • Patient is unable to ingest a solid dosage form due to ONE of the following

        • Age.

    Orenitram or Uptravi Initial Authorization

    Orenitram or Uptravi is covered for initial authorization when ALL criteria in ONE of the following pathways are met.

    ONE of the following pathways

    • Continuation-of-therapy pathway

      • Patient is continuing therapy with Orenitram or Uptravi.
      • Patient has not received a manufacturer-supplied sample at no cost in the prescriber's office or any form of assistance from a manufacturer-sponsored support program as a means to establish current use of Orenitram or Uptravi.
      • Patient is not taking Orenitram or Uptravi in combination with a prostanoid or prostacyclin analogue, such as epoprostenol, iloprost, or treprostinil.
      • The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    • New-therapy pathway

    PAH Reauthorization

    Covered for reauthorization when the applicable continuation criteria are met.

    Applicable product pathway

    • Documentation demonstrates that the patient is receiving clinical benefit from Adempas, Opsumit, Opsynvi, Letairis, Tracleer, Tyvaso, Tyvaso DPI, Ventavis, or Yutrepia therapy.
    • Revatio oral powder for suspension, Liqrev oral suspension, or Tadliq oral suspension

      • Documentation demonstrates that the patient is receiving clinical benefit from Revatio oral powder for suspension, Liqrev oral suspension, or Tadliq oral suspension therapy.
      • Patient remains unable to ingest a solid dosage form, such as an oral tablet, due to age, oral-motor difficulties, or dysphagia.
    • Orenitram or Uptravi

    CTEPH Initial Authorization

    Adempas is covered for initial authorization for chronic thromboembolic pulmonary hypertension (CTEPH) when the applicable CTEPH pathway is met.

    ONE of the following CTEPH pathways

    • ALL of the following

      • Diagnosis of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
      • CTEPH is symptomatic.
      • The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    • ALL of the following

      • Patient is currently receiving any therapy for the diagnosis of CTEPH.

    Adempas Initial Authorization for CTEPH

    Adempas initial authorization for CTEPH requires ONE of the following disease/symptom or current-therapy pathways.

    ONE of the following

    • Disease and symptom pathway

      • Diagnosis of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
      • CTEPH is symptomatic.
      • Adempas is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    • Current-therapy pathway

      • Patient is currently receiving any therapy for the diagnosis of CTEPH.

    Adempas Reauthorization

    Covered for CTEPH reauthorization when the continuation criterion is met.

    Documentation demonstrates that the patient is receiving clinical benefit from Adempas therapy.

    Initial Tyvaso, Tyvaso DPI, or Yutrepia Therapy

    Initial Tyvaso, Tyvaso DPI, or Yutrepia therapy is covered when ALL of the following criteria are met.

    ALL of the following

    • Disease criteria

      • Diagnosis of pulmonary hypertension associated with interstitial lung disease (WHO group 3) is confirmed by right heart catheterization.
      • Interstitial lung disease is diagnosed based on evidence of diffuse parenchymal lung disease on computed tomography of the chest.
      • Pulmonary hypertension is symptomatic.
    • Tyvaso, Tyvaso DPI, or Yutrepia is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.

    Tyvaso, Tyvaso DPI, or Yutrepia Reauthorization

    Covered for reauthorization when the continuation criterion is met.

    Documentation demonstrates a positive clinical response to Tyvaso, Tyvaso DPI, or Yutrepia therapy, such as improved exercise ability.

    These criteria apply only to the oral suspension formulations of sildenafil citrate. The intravenous formulation is not self-administered and is therefore not covered under the pharmacy benefit.

    Orenitram or Uptravi may not be used in combination with a prostanoid or prostacyclin analogue, such as epoprostenol, iloprost, or treprostinil.

    State mandates may apply. Federal regulatory requirements and the member-specific benefit plan may also impact coverage criteria. Other policies and utilization management programs may apply.

    Brand Letairis, Liqrev oral suspension, Opsumit, Opsynvi, and Revatio oral powder for suspension are typically excluded from coverage. Tried/failed criteria may be in place; refer to plan specifics to determine exclusion status.

    Endothelin receptor antagonists, including Letairis, Opsumit, Opsynvi, and Tracleer, should be used with caution in patients with liver disease. Use is not recommended in moderate to severe hepatic impairment. Tracleer product labeling includes a black box warning regarding the risk of liver injury. Prescribers should consider whether benefits outweigh the risk in WHO Class II patients, as early liver injury may preclude future use as disease progresses.

    Administration of oral PDE-5 inhibitors, including Liqrev, Opsynvi, Revatio powder for oral suspension, and Tadliq, with any form of organic nitrate, regularly or intermittently, is contraindicated. Concomitant administration of oral PDE-5 inhibitors with Adempas is also contraindicated.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Obtain prior authorization before initiating or continuing covered pulmonary hypertension therapies. Initial authorization criteria vary by product and diagnosis, and approval is generally issued for 12 months.

    • PAH products include Adempas, Letairis, Opsumit, Opsynvi, Tracleer, Tyvaso, Tyvaso DPI, Ventavis, and Yutrepia.
    • Suspension products Revatio oral powder for suspension, Liqrev oral suspension, and Tadliq oral suspension require additional inability-to-ingest-solid-dosage-form criteria.
    • Orenitram and Uptravi have continuation or prerequisite-therapy requirements.
    • Adempas for CTEPH requires diagnosis-specific initial authorization criteria.
    Documentation Required

    Reauthorization Requires Clinical Benefit

    For reauthorization, submit documentation that the patient is receiving clinical benefit. Suspension products also require documentation that the patient remains unable to ingest a solid dosage form, and Orenitram or Uptravi must not be combined with a prostanoid or prostacyclin analogue.

    Clinical Background

    Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by elevated pressure in the vessels carrying blood between the heart and lungs. It can lead to ventricular dysfunction, reduced exercise capacity, right-sided heart failure, and death. The policy primarily addresses medications used for WHO Group 1 PAH, including endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogs, soluble guanylate cyclase stimulators, and an activin-signaling ligand.

    Condition Definitions

    Pulmonary arterial hypertension (PAH)
    DefinitionPulmonary arterial hypertension (PAH) is characterized by elevated pressure in the vessels that carry blood between the heart and the lungs.
    Disease coursePAH is often progressive and may result in ventricular dysfunction, reduced exercise capacity, right-sided heart failure, and death.
    Primary population addressedThe policy primarily addresses PAH classified as WHO Group 1.
    Chronic thromboembolic pulmonary hypertension (CTEPH)
    DefinitionChronic thromboembolic pulmonary hypertension (CTEPH) is pulmonary hypertension associated with chronic thromboembolic disease.
    Persistent or recurrent diseaseCTEPH may be persistent or recurrent after surgical treatment.

    Initial Therapy Criteria

    PAH Initial Therapy

    Initial PAH therapy requires the applicable diagnosis or treatment pathway and specialist involvement.

    PAH initial therapy

    • Symptomatic PAH pathway

      • Pulmonary arterial hypertension is symptomatic and confirmed by right heart catheterization.
      • The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    • Current-therapy pathway

      • The patient is currently receiving any therapy for pulmonary arterial hypertension.

    Continuation and Reauthorization Criteria

    PAH Continuation Therapy

    Reauthorization is available when the applicable product-specific continuation criteria are met.

    PAH continuation therapy

    • Documentation shows that the patient is receiving clinical benefit from the applicable PAH therapy.
    • Additional product-specific requirement

      • For oral suspension products, the patient remains unable to ingest a solid dosage form because of age, oral-motor difficulties, or dysphagia.
      • For Orenitram or Uptravi, the patient is not taking the requested therapy in combination with a prostanoid or prostacyclin analogue.
      • No additional product-specific requirement applies to the standard PAH products.

    Step-Therapy Requirements

    StepRequired prior therapyFailure criterion
    1One PDE-5 inhibitor or Adempas, and one endothelin receptor antagonist (ERA)History of failure, contraindication, or intolerance to both therapy groups
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyPrior Authorization/Medical Necessity – PAH Agents
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewAug 1, 2025
    Next Review DateN/A
    Key ActionSubmit documentation of the applicable diagnosis, required diagnostic confirmation, current therapy or clinical benefit, and specialist prescribing or consultation when seeking authorization.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsClinical BackgroundCondition DefinitionsInitial Therapy CriteriaContinuation and Reauthorization CriteriaStep-Therapy Requirements
    Oral-motor difficulties.
  1. Dysphagia.
  2. The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    • ONE of the following

      • ALL of the following

        • Pulmonary arterial hypertension is symptomatic.
        • Diagnosis of pulmonary arterial hypertension is confirmed by right heart catheterization.
      • Patient is currently receiving any therapy for the diagnosis of pulmonary arterial hypertension.
    • History of failure, contraindication, or intolerance to BOTH of the following

      • ANY of the following

        • A PDE-5 inhibitor, such as sildenafil citrate (generic Revatio) or tadalafil (generic Adcirca).
        • Adempas.
      • ANY of the following

        • An ERA, such as ambrisentan (generic Letairis), Opsumit, or bosentan (generic Tracleer).
    • Patient is not taking Orenitram or Uptravi in combination with a prostanoid or prostacyclin analogue, such as epoprostenol, iloprost, or treprostinil.
    • The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    Documentation demonstrates that the patient is receiving clinical benefit from Orenitram or Uptravi therapy.
  3. Patient is not taking Orenitram or Uptravi in combination with a prostanoid or prostacyclin analogue, such as epoprostenol, iloprost, or treprostinil.
  4. The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    Adempas is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    • Reauthorization is generally issued for 12 months.
    • For Revatio oral powder for suspension, Liqrev oral suspension, or Tadliq oral suspension, document continued inability due to age, oral-motor difficulties, or dysphagia.
    • For Orenitram or Uptravi, document clinical benefit and absence of prohibited combination therapy.
    Prior Authorization

    Adempas Initial Authorization for CTEPH

    For initial Adempas authorization for CTEPH, document the qualifying diagnosis or current CTEPH therapy and specialist involvement.

    • Document inoperable or persistent/recurrent CTEPH, or symptomatic CTEPH, when applicable.
    • Alternatively, document that the patient is currently receiving therapy for CTEPH.
    • Adempas must be prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    Documentation Required

    Document Adempas Clinical Benefit

    For Adempas continuation, submit documentation that the patient is receiving clinical benefit from Adempas therapy.

    • Reauthorization is generally issued for 12 months.
    Prior Authorization

    Prior Authorization for Group 3 Treprostinil Therapy

    Obtain prior authorization for Tyvaso, Tyvaso DPI, or Yutrepia when treating pulmonary hypertension associated with interstitial lung disease (WHO group 3).

    • Document symptomatic pulmonary hypertension confirmed by right-heart catheterization.
    • Document interstitial lung disease based on evidence of diffuse parenchymal lung disease on chest computed tomography.
    • The medication must be prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.

    Unsupported block type: documentation

    Step Therapy

    Step Requirement for Orenitram or Uptravi

    For initial Orenitram or Uptravi authorization, document failure, contraindication, or intolerance to both prerequisite therapy groups.

    • One prerequisite group is a PDE-5 inhibitor, such as sildenafil or tadalafil, or Adempas.
    • The other prerequisite group is an endothelin receptor antagonist (ERA), such as ambrisentan, Opsumit, or bosentan.
    • The medication must be prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: step_therapy

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Inoperable diseaseCTEPH may also be inoperable and is identified as WHO Group 4 disease.
    Pulmonary hypertension associated with interstitial lung disease
    DefinitionPulmonary hypertension associated with interstitial lung disease is pulmonary hypertension occurring in the setting of interstitial lung disease.
    WHO classificationThis condition is identified as WHO group 3 pulmonary hypertension.
    Diagnostic confirmationThe diagnosis is confirmed by right heart catheterization, with interstitial lung disease supported by evidence of diffuse parenchymal lung disease on computed tomography of the chest.
    Chronic thromboembolic pulmonary hypertension (CTEPH)
    DefinitionChronic thromboembolic pulmonary hypertension (CTEPH) is pulmonary hypertension associated with chronic thromboembolic disease.
    Qualifying diseaseThe policy includes inoperable CTEPH and persistent or recurrent CTEPH after surgical treatment.
    Symptomatic diseaseThe CTEPH authorization pathway includes symptomatic CTEPH or current therapy for the diagnosis of CTEPH.
    The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.

    Oral suspension pathway

    • ANY of the following

      • Pulmonary arterial hypertension is symptomatic and confirmed by right heart catheterization.
      • The patient is currently receiving any therapy for pulmonary arterial hypertension.
    • The patient is unable to ingest a solid dosage form because of age, oral-motor difficulties, or dysphagia.
    • The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.

    Orenitram or Uptravi Initial Therapy

    Initial Orenitram or Uptravi authorization follows either a continuation or prior-treatment pathway.

    Orenitram or Uptravi initial therapy

    • Continuation pathway

      • The request is for continuation of therapy.
      • No manufacturer-supplied sample or manufacturer-sponsored assistance was used to establish current use.
      • The patient is not taking Orenitram or Uptravi with a prostanoid or prostacyclin analogue.
      • The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.
    • Prior-treatment pathway

      • ANY of the following

        • Pulmonary arterial hypertension is symptomatic and confirmed by right heart catheterization.
        • The patient is currently receiving any therapy for pulmonary arterial hypertension.
      • The patient has a history of failure, contraindication, or intolerance to both a PDE-5 inhibitor or Adempas and an endothelin receptor antagonist.
      • The patient is not taking Orenitram or Uptravi with a prostanoid or prostacyclin analogue.
      • The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.

    Adempas for CTEPH

    Adempas initial therapy is addressed for inoperable, persistent/recurrent, or symptomatic CTEPH and for patients currently receiving CTEPH therapy.

    CTEPH eligibility

    • The patient has inoperable or persistent/recurrent CTEPH and symptomatic CTEPH.
    • The patient is currently receiving any therapy for CTEPH.

    Adempas Initial CTEPH Therapy

    Adempas initial CTEPH therapy follows one of two eligibility pathways and requires specialist prescribing or consultation.

    Adempas CTEPH initial therapy

    • Eligibility pathway

      • Disease and symptom pathway

        • The patient has inoperable or persistent/recurrent CTEPH.
        • CTEPH is symptomatic.
      • Current-therapy pathway

        • The patient is currently receiving any therapy for CTEPH.
    • Adempas is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.

    Tyvaso, Tyvaso DPI, or Yutrepia Initial Therapy

    Initial Tyvaso, Tyvaso DPI, or Yutrepia therapy requires both the diagnostic and specialist criteria groups.

    Initial group 3 pulmonary hypertension therapy

    • Diagnostic criteria

      • Pulmonary hypertension associated with interstitial lung disease (WHO group 3) is confirmed by right heart catheterization.
      • Interstitial lung disease is supported by evidence of diffuse parenchymal lung disease on computed tomography of the chest.
      • Pulmonary hypertension is symptomatic.
    • Specialist criteria

      • The medication is prescribed by or in consultation with a cardiologist, pulmonologist, or rheumatologist.

    Adempas Continuation

    Adempas reauthorization requires clinical benefit.

    Adempas continuation

    • Documentation shows that the patient is receiving clinical benefit from Adempas therapy.

    Tyvaso, Tyvaso DPI, or Yutrepia Continuation

    Tyvaso, Tyvaso DPI, or Yutrepia reauthorization requires positive clinical response.

    Treprostinil continuation

    • Documentation shows a positive clinical response to Tyvaso, Tyvaso DPI, or Yutrepia therapy, such as improved exercise ability.